clinical trial · NCT04033445
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC·phase3·active not recruiting·n = 1,064
Ulcerative ColitisPlaceboGuselkumab
brief summary
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).
started
Sep 26, 2019
primary completion
Sep 19, 2023
completion
Jul 16, 2027
last updated
Sep 28, 2026
official title
CNTO1959UCO3001: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol